Efficacy and safety of clarithromycin as treatment for Mediterranean spotted fever in children: A randomized controlled trial

被引：33
作者：
Cascio, A
Colomba, C
Di Rosa, D
Salsa, L
di Martino, L
Titone, L
机构：
[1] Univ Palermo, Ist Patol Infett & Virol, Osped G Di Cristina, I-90134 Palermo, Italy
[2] Azienda Osped Santobono Pausillipon, Unita Operat Pediat Infettivol, Naples, Italy
来源：
CLINICAL INFECTIOUS DISEASES | 2001年 / 33卷 / 03期
关键词：
D O I：
10.1086/321864
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
Fifty-one children with Mediterranean spotted fever (MSF) were randomized to receive either clarithromycin, 15 mg/kg/ day orally in 2 divided doses, or chloramphenicol, 50 mg/ kg/day orally in 4 divided doses, for 7 days. Mean time to defervescence was 36.7 h in the clarithromycin group and 47.1 h in the chloramphenicol group (P=.047). Clarithro- mycin could be an acceptable therapeutic alternative to chloramphenicol and to tetracyclines for children aged <8 years with MSF.
引用
收藏
页码：409 / 411
页数：3
相关论文
共 10 条
[1]   RANDOMIZED TRIAL OF DOXYCYCLINE VERSUS JOSAMYCIN FOR MEDITERRANEAN SPOTTED-FEVER [J].
BELLA, F ;
FONT, B ;
URIZ, S ;
MUNOZ, T ;
ESPEJO, E ;
TRAVERIA, J ;
SERRANO, JA ;
SEGURA, F .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1990, 34 (05) :937-938
[2]   Clinical and laboratory findings of boutonneuse fever in Sicilian children [J].
Cascio, A ;
Dones, P ;
Romano, A ;
Titone, L .
EUROPEAN JOURNAL OF PEDIATRICS, 1998, 157 (06) :482-486
[3]   In vitro susceptibilities of Bartonella henselae, B-quintana, B-elizabethae, Rickettsia rickettsii, R-conorii, R-akari, and R-prowazekii to macrolide antibiotics as determined by immunofluorescent-antibody analysis of infected vero cell monolayers [J].
Ives, TJ ;
Manzewitsch, P ;
Regnery, RL ;
Butts, JD ;
Kebede, M .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (03) :578-582
[4]   In vitro susceptibilities of Rickettsia and Bartonella spp. to 14-hydroxy-clarithromycin as determined by immunofluorescent antibody analysis of infected Vero cell monolayers [J].
Ives, TJ ;
Marston, EL ;
Regnery, RL ;
Butts, JD ;
Majerus, TC .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2000, 45 (03) :305-310
[5]  
MCDONALD JC, 1988, AM J MED, V85, P799, DOI 10.1016/S0002-9343(88)80024-X
[6]   Azithromycin vs doxycycline for Mediterranean spotted fever [J].
Meloni, G ;
Meloni, T .
PEDIATRIC INFECTIOUS DISEASE JOURNAL, 1996, 15 (11) :1042-1044
[7]   ERYTHROMYCIN VERSUS TETRACYCLINE FOR TREATMENT OF MEDITERRANEAN SPOTTED-FEVER [J].
MUNOZESPIN, T ;
LOPEZPARES, P ;
ESPEJOARENAS, E ;
FONTCREUS, B ;
MARTINEZVILA, I ;
TRAVERIACASANOVA, J ;
SEGURAPORTA, F ;
BELLACUETO, F .
ARCHIVES OF DISEASE IN CHILDHOOD, 1986, 61 (10) :1027-1029
[8]  
RAOULT D, 1992, EUR J EPIDEMIOL, V8, P192, DOI 10.1007/BF00144799
[9]   Rickettsioses as paradigms of new or emerging infectious diseases [J].
Raoult, D ;
Roux, V .
CLINICAL MICROBIOLOGY REVIEWS, 1997, 10 (04) :694-+
[10]   In vitro susceptibilities of 27 rickettsiae to 13 antimicrobials [J].
Rolain, JM ;
Maurin, M ;
Vestris, G ;
Raoult, D .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (07) :1537-1541
1